Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;24(8):689-695.e1.
doi: 10.1016/j.cllc.2023.09.001. Epub 2023 Sep 17.

Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

Aakash Desai  1 , Caleb J Smith  1 , Yash Ashara  1 , Jacob J Orme  1 , Saurabh Zanwar  1 , Ashley Potter  1 , Craig Hocum  1 , J Nicole Moffett  1 , Anna J Schwecke  1 , Rami Manochakian  1 , Yanyan Lou  2 , Yujie Zhao  2 , Vinicius Ernani  3 , Panos Savvides  3 , Julian Molina  1 , Anastasios Dimou  1 , Aaron S Mansfield  1 , Kaushal Parikh  1 , Konstantinos Leventakos  4
Affiliations
Free article

Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

Aakash Desai et al. Clin Lung Cancer. 2023 Dec.
Free article

Abstract

Background: Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While clinical trials have demonstrated its efficacy and safety, real-world data are limited. This study aimed to evaluate the safety and efficacy of lurbinectedin in a real-world setting, focusing on its use as a second-line agent and beyond in SCLC patients.

Methods: A retrospective analysis was conducted on 90 patients who received lurbinectedin between June 2020 and June 2022 within the Mayo Clinic Health System. Of these, 50 patients received lurbinectedin as a second-line agent, and 14 patients received it as a third-line or later agent. The primary outcomes assessed were overall survival (OS), progression-free survival (PFS), and treatment-related adverse events.

Results: Lurbinectedin was generally well tolerated in this real-world cohort, with a median OS of 5.1 months in the second-line cohort and 5.6 months in the third-line or later cohort. Median PFS was 2.1 months in the second-line cohort and 3.4 months in the third-line or later cohort. Adverse events were manageable, with the most common being neutropenia, anemia, fatigue, and febrile neutropenia. No treatment-related deaths or grade 5 toxicities were reported.

Conclusion: This real-world study provides valuable insights into the safety and efficacy of lurbinectedin in relapsed SCLC. Lurbinectedin demonstrated modest efficacy and a comparable safety profile to that observed in clinical trials. However, outcomes for relapsed SCLC remain suboptimal, particularly for patients with a shorter chemotherapy-free interval and central nervous system metastases.

Keywords: Lurbinectedin; Real world evidence; SCLC; Second line; Small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure A.D: Advisory board: Amgen, Sanofi. C.S, Y.A, J.O, S.Z, A.P, C.H, N.M, A.S, J.M, Y.Z, P.S, K.P: Reports no relevant conflicts of interest. R.M: Consulting/advisory board for: AstraZeneca, Turning points, Janssen, Takeda, Y.L: Advisory board: AstraZeneca Pharmaceuticals, Janssen Pharmaceutical, Lilly Oncology, Turning point therapeutics, Consultant: AstraZeneca, Honorarium: clarion health care, Research Funding Support: Merck, MacroGenics, Tolero Pharmaceuticals, AstraZeneca, Vaccinex, Blueprint Medicines, Harpoon Therapeutics, Sun Pharma Advanced Research, Bristol-Myers Squibb, Kyowa Pharmaceuticals, Tesaro, Bayer HealthCare, Mirati Therapeutics, Daiichi Sankyo, V.E: Consulting/advisory board for: AstraZeneca, Daiichi Sanyo, Jazz Pharmaceuticals, Bayer, Pfizer, and Novocure, A.D: Advisory board: TP Therapeutics, Guardant Health, Chromacode, Anheart Therapeutics., A.S.M: is supported by a Mark Foundation ASPIRE Award, NCI R21 CA251923, and Department of Defense W81XWH-22-1-0021 Concept Award. Advisory Boards: AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Inc., Janssen; Travel support and honoraria from Shanghai Roche Pharmaceuticals Ltd., and is non-remunerated member of the Mesothelioma Applied Research Foundation and Friends of Patan Hospital Board of Directors. K.L: consulting activities with Boehringer Ingelheim Pharmaceuticals, Amgen, AstraZeneca, Targeted Oncology, Takeda, Jazz Pharmaceuticals, Mirati Therapeutics, Janssen, and Regeneron; CME activities with OncLive and MJH Life Sciences; Research support (to institution) from AstraZeneca and Mirati Therapeutics.Clinical trial support: Novartis, Syntrix Therapeutics, Sorrento Therapeutics, Anheart Therapeutics, Merck; Honoraria: Roche/Genentech, Intellisphere.

MeSH terms